Personal Information

Jian Ma, Ph.D., Professor of pathology and pathophysiology, mentor for Ph.D. students. Currently, He is the vice director of Cancer Research Institute of Central South University, vice director of Hunan Key Laboratory of Nonresolving Inflammation and Cancer, vice president of Hunan Society for Immunology. He received his medicine bachelor degree from Hunan Medical University, and his Ph.D. degree from Central South University. He was enrolled in the Program for New Century Excellent Talents in University of the Chinese Ministry of Education. He has been awarded with multiple grants from Natural Science Foundation of China, Hunan Province Science and Technology Project, Hunan Science Foundation for Distinguished Young Scholars, etc.

His research team is interested in:

  (1) Epstein-Barr virus infection and tumorigenesis and tumor immunology.

  (2) Nonresolving inflammation and cancer, especially the inflammatory bowl disease, mouse model, prevention, therapy.

  (3) Key molecules involved in tumorigenesis and tumor immunology, such as Lactoferrin, YAP1, and EphA2.

Email: majian@csu.edu.cn

Recent publications (* corresponding authors):

1)      Peng Q, Wang L, Wang J, Liu C, Zheng X, Zhang X, Wei L, Li Z, Wu Y, Wen Y, Cao P, Liao Q, Yan Q*, Ma J*. Epstein-Barr Virus EBNA2 Phase Separation Regulates Cancer-associated Alternative RNA Splicing Patterns. Clinical and Translational Medicine. 2021;11(8):e504. PMID: 34459139. 

2)      Peng Q, Zhou Y, Oyang L, Wu N, Tang Y, Su M, Luo X, Wang Y, Sheng X, Ma J*. Liao Q*. Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. Molecular Therapy. 2021: S1525-0016(21)00581-5. PMID: 34793975

3)      Li Z, Zhang X, Liu C, Peng Q, Wu Y, Wen Y, Zheng R, Yan Q, Ma J*. Macrophage-biomimetic nanoparticles ameliorate ulcerative colitis through reducing inflammatory factors expression. Journal of Innate Immunity. 2021;1-13. PMID: 34724662

4)      Ou C, Sun Z, He X, Li X, Fan S, Zheng X, Peng Q, Li G, Li X*, Ma J*. Targeting YAP1/LINC00152/FSCN1 signaling axis prevents the progression of colorectal cancer. Advanced Science. 2019; 7(3): 1901380. PMID: 32042551

5)      Wei L, Liu C, Wang J, Zheng X, Peng Q, Ye Q, Qin Z, Li Z, Zhang X, Wu Y, Wen Y, Zhang X, Yan Q, Ma J*. Lactoferrin is required for early B cell development in C57BL/6 mice. Journal of Hematology & Oncology. 2021 Apr 7;14(1):58. PMID: 33827645.  

6)      Wei L, Zhang X, Wang J, Ye Q, Zheng X, Peng Q, Zheng Y, Liu P, Zhang X, Li Z, Liu C, Yan Q, Li G, Ma J*. Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid–derived suppressor cells in mice. Oncogene. Oncogene. 2020; 39(1): 122-135. PMID: 31462711

7)      Zheng X, Wang J, Zhang X, Fu Y, Peng Q, Lu J. Wei L. Li Z, Liu C, Wu Y, Yan Q*, Ma J*. RNA m6A methylation regulates virus–host interaction and EBNA2 expression during Epstein–Barr virus infection. Immunity, Inflammation and Disease. 2021;9(2):351-362, PMID: 33434416. 

8)      Peng Q, Wang L, Qin Z, Wang J, Zheng X, Wei L, Zhang X, Zhang X, Liu C, Li Z, Wu Y, Li G, Yan Q*, Ma J*. Phase separation of Epstein-Barr Virus EBNA2 and Its Coactivator EBNALP controls gene expression. Journal of Virology. 2020; 94(7): e01771-19. PMID: 31941785.  

9)      Li Z, Wang J, Zhang X, Liu P, Zhang X, Wang J, Zheng X, Wei L, Peng Q, Liu C,Yan Q, Shen S, Li X*, Ma J*. Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape. Journal of Immunology. 2020 May 1;204(9):2589-2599. PMID: 32198140.  

10)    Wang J, Zheng X, Qin Z, Wei L, Lu Y, Peng Q, Gao Y, Zhang X, Zhang X, Li Z, Fu Y, Liu P, Liu C, Yan Q, Xiong W, Li G, Lu J*, Ma J*. Epstein-Barr virus miR-BART3-3p promotes tumorigenesis by regulating the senescence pathway in gastric cancer. Journal of Biological Chemistry. 2019;294(13):4854–4866. PMID: 30674552

11)    Zheng X, Wang J, Wei L, Peng Q, Gao Y, Fu Y, Lu Y, Qin Z, Zhang X, Lu J, Ou C, Li Z, Zhang X, Liu P, Xiong W, Li G, Yan Q, Ma J*. Epstein-Barr Virus miR-BART5-3p inhibits p53 expression. Journal of Virology. 2018; 92(23): e01022-18. PMID: 30209170.

12)    Peng Q, Chen L, Wu W, Wang J, Zheng X, Chen Z, Jiang Q, Han J, Wei L, Wang L, Huang J*, Ma J*. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer. Cell Death & Disease. 2018;9(12):1146. PMID: 30451837

13)    Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J*. S100A8/A9 in Inflammation. Frontiers in Immunology. 2018; 9:1298. PMID: 29942307.

14)    Ou C, Sun Z, Li X, Li X, Ren W, Qin Z, Zhang X, Yuan W, Wang J, Yu W, Zhang S, Peng Q, Yan Q, Xiong W, Li G*, Ma J*. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. Cancer Letters. 2017; 399: 53-63. PMID: 28433598.

15)    Zhang X, Wei L, Wang J, Qin Z, Wang J, Lu Y, Zheng X, Peng Q, Ye Q, Ai F, Liu P, Wang S, Li G, Shen S, Ma J*. Suppression colitis and colitis-associated colon cancer by anti-S100a9 antibody in mice. Frontiers in Immunology. 2017; 8:1774. PMID: 29326691  

16)    Lu Y, Qin Z, Wang J, Zheng X, Lu J, Zhang X, Wei L, Peng Q, Zheng Y, Ou C, Ye Q, Xiong W, Li G, Fu Y, Yan Q*, Ma J*. Epstein-Barr Virus miR-BART6-3p Inhibits the RIG-I Pathway. Journal of Innate Immunity. 2017;9(6):574-586. PMID: 28877527.

17)    Ren W, Shen S, Sun Z, Shu P, Shen X, Bu C, Ai F, Zhang X, Tang A, Tian L, Li G, Li X*, Ma J*. Jak-STAT3 pathway triggers DICER1 for proteasomal degradation by ubiquitin ligase complex of CUL4ADCAF1 to promote colon cancer development. Cancer Letters. 2016; 375(2): 209-220. PMID: 26965998.

18)    Qin Z, He W, Tang J, Ye Q, Dang W, Lu Y, Wang J, Li G, Yan Q*, Ma J*. MicroRNAs provide feedback regulation of epithelial-mesenchymal transition induced by growth factors. Journal of Cellular Physiology. 2016; 231(1):120-129. PMID: 26032086.

19)    Zhang X, Ai F, Li X, She X, Li N, Tang A, Qin Z, Ye Q, Tian L, Li G, Shen S*, Ma J*. Inflammation-induced S100A8 activates Id3 and promotes colorectal tumorigenesis. International Journal of Cancer. 2015;137(12):2803-14. PMID: 26135667.

20)    Zheng Y, Qin Z, Ye Q, Chen P, Wang Z, Yan Q, Luo Z, Liu X, Zhou Y, Xiong W, Ma J*, Li G*. Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9. Laboratory Investigation.2014;94(11): 1188-1199. PMID: 25068657.  

21)    Deng M, Zhang W, Tang H, YeQ, Liao Q, Zhou Y, Wu M, Xiong W, Zheng Y, Guo X, Qin Z, He W, Zhou M, Xiang J, Li X, Ma J*, Li G*. Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 2013; 32(36): 4273-4283. PMID: 23069661.

22)    Tang A, Li N, Li X, Yang H,Wang W, Zhang L, Li GY, Xiong W, Ma J*, Shen S*. Dynamic activation of the key pathways: linking colitis to colorectal cancer in a mouse model. Carcinogenesis.2012, 33(7): 1375-1383. PMID: 22610167.

23)    Zheng Y, Zhang W,Ye Q, ZhouY, Xiong W, He W, Deng M, Zhou M, GuoX, Chen P, Fan S, Liu X, Wang Z, Li X, Ma J*,Li G*. Inhibition of Epstein-Barr virus infection by lactoferrin. Journal of Innate Immunity. 2012,4(4): 387-398. PMID: 22433582.

24)    Deng M, Tang H, Zhou Y, ZhouM, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, Li X, Ma J*, Li G*. MiR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of Cell Science. 2011; 124(17): 2997-3005. PMID: 21878506.